KDM4A and primary effusion lymphoma: Together with the long-acknowledged oncogenic role of KDM4A in inhibiting apoptosis (28, 29), we hypothesize that targeting KDM4A or its SUMO modification may reduce infectious viral particle production, prevent viral antiapoptotic effects, and be a potential therapeutic option to kill PEL cells.